Background:In a subgroup of patients with multiple sclerosis natalizumab therapy causes generation of anti-natalizumab antibodies that may be transient or persistent. It is recommended to discontinue natalizumab therapy in persistently antibody-positive patients.
Objective:To use titres of anti-natalizumab antibodies to predict persistency of antibodies.
Patients and methods:In 525 consecutive natalizumab treated patients tested for anti-natalizumab antibodies 43 (8.2%) were antibody-positive. Thirty of the antibody-positive patients, who were tested both at three and at six months after treatment start, had antibody titres in blood measured using an extended ELISA method.
Results:Samples from persistently positive patients (N=18) had higher titre values than samples from transiently positive patients (N=12). A cut-off value for high titre values was generated, above which patients may discontinue natalizumab therapy after three months. The method had a sensitivity of 0.83, a specificity of 1.00 and a diagnostic accuracy of 0.90.
Conclusion:An extended ELISA method for measuring anti-natalizumab antibody titres in multiple sclerosis patients on natalizumab therapy may be used for evaluation of antibody persistence. A test at three months may identify patients with high titres, who should discontinue natalizumab therapy, and patients with transient low-titre antibodies, who may continue natalizumab therapy despite development of antibodies.
FrenettePSWagnerDD. Adhesion molecules – Part 1. N Engl J Med1996; 334: 1526–1529.
2.
StüveOBennettJL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev2007; 13: 79–95.
3.
MillerDHKhanOASheremataWA. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
4.
PolmanCHConnorPWHavrdovaE. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
5.
RudickRAStuartWHCalabresiPA. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
6.
CalabresiPAGiovannoniGConfavreuxC. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology2007; 69: 1391–1403.
7.
HutchinsonMKapposLCalabresiPA. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol2009; 256: 405–415.
8.
OturaiABKoch-HenriksenNPetersenT. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: A Danish nationwide study. Eur J Neurol2009; 16: 420–423.
9.
PutzkiNYaldizliÖBühlerR. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: Results from a multicenter study in Switzerland. Eur Neurol2010; 63: 101–106.
10.
SangalliFMoiolaLBucelloS. Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: A post-marketing observational study. Neurol Sci2011; 31(Suppl. 3): S299–S302.
11.
SorensenPSJensenPEHaghikiaA. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler2011; 17: 1074–1078.
